The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC).
Harry Raftopoulos
Research Funding - Eisai
Joseph Aisner
Research Funding - Cancer Institute of New Jersey, UMDNJ
Kirushna Kumar
Research Funding - Eisai
Sanjay Goel
Research Funding - Eisai
Christian Dittrich
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Minish Jain
No relevant relationships to disclose
Prashanth Gopalakrishna
Employment or Leadership Position - Eisai
Paloma Salazar
Employment or Leadership Position - Eisai
Beverley Jones
Consultant or Advisory Role - Eisai
Daniel Peter Petrylak
Research Funding - Eisai